Evidence map›Paper›PMID 37499736›Full record

ArticleContraception2023

Development and validation of an expanded panel of progestins using liquid chromatography-tandem triple quadrupole mass spectrometry to monitor protocol compliance in hormonal contraceptive pharmacokinetic/pharmacodynamic studies.

Jeffrey T Jensen, Bethany T Waites, Emily R Boniface, Sara McCrimmon, Steven Blue, David W Erikson

Open access · greenAbstract read
In one paragraph

Article in Contraception, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jeffrey T JensenDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States. Electronic address: jensenje@ohsu.edu.
Bethany T WaitesDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States.
Emily R BonifaceDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States.
Sara McCrimmonDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States.
Steven BlueEndocrine Technologies Core, Oregon National Primate Research Center, Beaverton, OR, United States.
David W EriksonEndocrine Technologies Core, Oregon National Primate Research Center, Beaverton, OR, United States.
Oregon Health & Science University · USOregon National Primate Research Center · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI WONG, SCOTT W · 1985 to 2011
$140.8M
NCRR NIH HHS P51 RR000163NIH HHS P51 OD011092
6 · The paper itself

Abstract

We developed and validated the use of ultra-high-performance liquid chromatography-heated electrospray ionization-tandem triple quadrupole mass spectrometry to simultaneously analyze serum concentrations of ethinylestradiol, dienogest, norelgestromin, norethindrone, gestodene, levonorgestrel, etonogestrel, segesterone acetate, medroxyprogesterone acetate, and drospirenone. The calibration range for all targets was 0.009-10 ng/mL, with lower limit of quantification of 0.009 ng/mL for all analytes except gestodene (0.019 ng/mL). We used our assay to check compliance among participants in a clinical trial, confirmed the use of drospirenone in 11 of 13 study participants, and evidence of noncompliant progestins in 2 (levonorgestrel = 1, norethindrone = 1). We conclude that this approach provides an accurate method to check protocol compliance in contraceptive clinical trials. IMPLICATIONS: The availability of a liquid chromatography-tandem triple quadrupole mass spectrometry multiprogestin analysis panel for simultaneous evaluation of the most common contraceptive steroids approved worldwide could improve monitoring of compliance and protocol adherence in clinical trials.

Indexed as

Contraceptive AgentsProgestinsChromatography, LiquidClinical Trials as TopicGuideline AdherenceHumansLevonorgestrelMass SpectrometryNorethindroneReproducibility of ResultsContraceptive AgentsLevonorgestrelNorethindroneProgestinsAssaysComplianceLiquid chromatographyProgestins

Identifiers

PMID37499736
PMCPMC10528587
OpenAlexW4385232795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.